Projects

Projects per year 2015 2019 2020 2021 2023 2024 2028

• 1 Not started
• 20 Finished
• 21 Active

Projects per year

Search results

• Active

  ANI392: Using tumor-derived dendritic cells as novel therapeutic options against ovarian cancer

  Laoui, D. & Caro, A. A.

  1/11/24 → 31/10/25

  Project: Fundamental

• FWOTM1267: Remote control: the impact of primary non-small cell lung carcinoma tumors on circulating classical monocyte ontogeny, epigenomic rewiring, functionality and differentiation potential

  Stanley Joseph, K. J., Van Ginderachter, J. & Laoui, D.

  1/11/24 → 31/10/28

  Project: Fundamental

• FWOTM1221: Unraveling the mechanisms underlying dendritic cell clustering within the tumor microenvironment

  Hamouda, A. E. I. & Laoui, D.

  1/10/24 → 30/09/27

  Project: Fundamental

• OZR4308: OZR opvangmandaat post doc Federica Cappellesso

  Laoui, D. & Cappellesso, F.

  1/10/24 → 30/09/25

  Project: Fundamental

  • Tumor Microenvironment 100%
  • Diphtheria Toxin 80%
  • Membranes 57%
  • Neoplasms 37%
  • Recombinant Fusion Proteins 27%

• HERC66: 3D-CELLMAP: Unveiling complex cellular interactions in tissues through 3D super-resolution protein multiplex imaging

  Movahedi, K., Rooman, I., Sermon, K., De Bundel, D., Fioravanti, A., Staels, W., Magez, S., Breckpot, K., De Kock, J., Laoui, D., Goyvaerts, C., Smolders, I., Van Ginderachter, J., Marcelino Rodrigues, R., De Leu, N., van Grunsven, L., Hernot, S., Peeters, E., Vanhaecke, T., De Veirman, K., Ruytinx, J., Van Schependom, J., Kortekaas, I. & Goossens, E.

  1/05/24 → 31/05/28

  Project: Fundamental

  • Tissue 100%
  • Imaging techniques 89%
  • Proteins 86%
  • Microscopic examination 50%
  • Multiplexing 48%

• OZR4286: Financiering MZW OZR: DELI-SORT: MACSQuant® Tyto for sterile DELicate Immune cells SORTing

  Laoui, D., Vanginderachter, J. A., Magez, S., Tuyaerts, S., Fioravanti, A., Devoogdt, N., Van der Henst, C., Raes, G., Stijlemans, B., Hadadi, E., De Trez, C., Ruytinx, J., Brunner, J., De Groof, T. & De Veirman, K.

  24/04/24 → 24/04/28

  Project: Fundamental

  • cells 100%
  • Tyto 97%
  • sorting 57%
  • droplets 53%
  • therapeutics 44%

• OZR4292: Financiering MZW OZR: Biolayer interferometry to study protein-protein and protein-ligand interactions

  Versées, W., Loris, R., Rooman, I., Laoui, D., Messens, J., Brunner, J., Stijlemans, B. & Ballet, S.

  24/04/24 → 24/04/28

  Project: Fundamental

  • Interferometry 100%
  • Ligands 38%
  • Proteins 30%
  • Temperature 9%
  • Thermodynamics 8%

• OZR4259: Bilateral cooperation within the framework of a joint doctoral project: benchfee for joint PhD VUB - KU Leuven, ABOO Afrah

  Laoui, D.

  10/01/24 → 9/01/28

  Project: Fundamental

• OZR4228: Bilateral cooperation within the framework of a joint doctoral project: benchfee for joint PhD VUB - KU Leuven, GORDUN-PEIRO Alícia

  Laoui, D.

  13/11/23 → 12/11/27

  Project: Fundamental

• FWOTM1197: Defining the cDC-cellular interactome in non-small cell lung carcinoma to unleash their full potential for cancer immunotherapies

  Allonsius, L. & Laoui, D.

  1/11/23 → 31/10/27

  Project: Fundamental

  • Non-Small Cell Lung Carcinoma 100%
  • Immunotherapy 98%
  • Neoplasms 36%

• FWOSB147: Development of tumor-derived dendritic cell therapies to prevent ovarian cancer metastasis

  Gordún Peiró, A. & Laoui, D.

  1/11/23 → 31/10/27

  Project: Fundamental

  • Cell- and Tissue-Based Therapy 100%
  • Ovarian Neoplasms 96%
  • Dendritic Cells 94%
  • Neoplasm Metastasis 65%
  • Neoplasms 34%

• ANI341: A translational cancer vaccination approach based on co-delivery of tumorantigen and Toll-like receptor agonists

  Laoui, D.

  1/01/23 → 31/12/26

  Project: Fundamental

  • Toll-Like Receptors 100%
  • Vaccination 73%
  • neoplasms 70%
  • vaccination 41%
  • antigens 34%

• iBOF/23/043: MATRACs: Membrane Anchoring TRAfficking Chimeras

  Laoui, D., Devoogdt, N., De Geest, B. & Lambrecht, B.

  1/01/23 → 31/12/26

  Project: Fundamental

  • Membranes 100%
  • Budgets 95%
  • Proteins 18%
  • Neoplasms 16%
  • Immune System 13%

• ANI335: Final steps in the pre-clinical development of cDC vaccination as novel therapy for nonsmall cell lung cancer.

  Laoui, D.

  1/01/23 → 31/12/26

  Project: Fundamental

  • Non-Small Cell Lung Carcinoma 100%
  • Vaccination 89%
  • Therapeutics 18%

• FWOSB136: Towards the rational design of cancer therapies combining tumorderived dendritic cell vaccinations with regulatory T

  Laoui, D., Deschoemaeker, S. & Bravo Melgar, J.

  1/11/22 → 31/10/26

  Project: Fundamental

  • Lung Neoplasms 100%
  • Neoplasms 95%
  • Dendritic Cells 75%
  • Vaccination 67%
  • Combined Vaccines 57%

• ANI294: Investigating the impact of PARP inhibitors on the tumor dendritic cell compartment in triple negative breast cancer to uncover novel treatment strategies

  Laoui, D. & Deschoemaeker, S.

  1/10/21 → 30/09/25

  Project: Fundamental

  • Poly(ADP-ribose) Polymerase Inhibitors 100%
  • Triple Negative Breast Neoplasms 81%
  • Dendritic Cells 45%
  • Neoplasms 21%
  • Breast Neoplasms 16%

• OZR3763: Unleashing the full potential of cDC-based immunotherapies

  Laoui, D.

  1/07/21 → 31/08/25

  Project: Fundamental

  • Dendritic Cells 100%
  • immunotherapy 79%
  • dates (fruit) 47%
  • Tumors 24%
  • Immune system 14%

• ANI285: cDC2s: new players in the tumor microenvironment and cancer immunotherapy

  Laoui, D. & Nana, F. A.

  1/03/21 → 28/02/25

  Project: Fundamental

  • Tumor Microenvironment 100%
  • Financial Management 88%
  • Immunotherapy 84%
  • Neoplasms 49%
  • Dendritic Cells 34%

• FWOAL1009: Deciphering the dendritic cell compartment in ovarian cancer to assess their potential as tumor vaccines.

  Laoui, D.

  1/01/21 → 31/12/24

  Project: Fundamental

  • Ovarian Neoplasms 100%
  • Cancer Vaccines 78%
  • Dendritic Cells 58%
  • Poly(ADP-ribose) Polymerase Inhibitors 13%
  • Neoplasms 6%

• ANI252: Tumor-derived dendritic cell vaccinations as novel approach for the prevention of cancer relapse and metastasis

  Laoui, D.

  1/07/20 → 30/06/25

  Project: Fundamental

  • Dendritic Cells 100%
  • Secondary Prevention 95%
  • Vaccination 93%
  • Neoplasm Metastasis 71%
  • Neoplasms 60%

• IOF3009: GEAR: Integrating a multimodal approach to address current challenges in immunotherapy (INTEGRAL)

  Lahoutte, T., Devoogdt, N., Keyaerts, M., Van Ginderachter, J., Laoui, D., Raes, G., Breckpot, K., Goyvaerts, C., Raes, G., Bridoux, J. & Baudhuin, H. V.

  1/01/20 → 30/06/25

  Project: Applied

  • Immunotherapy 100%
  • Molecular Imaging 66%
  • Allergy and Immunology 60%
  • Physiologic Monitoring 60%
  • Drug Development 53%
• Not started

  ANI320: Defining the tumor-cDC cellular interactome to unleash their full potential for cancer immunotherapies

  Laoui, D. & Allonsius, L.

  Project: Fundamental

• Finished

  ANI359: Defining the cDC-cellular interactome in non-small cell lung carcinoma to unleash their full potential for cancer immunotherapies

  Laoui, D. & Allonsius, L.

  1/11/23 → 31/10/24

  Project: Fundamental

  • Non-Small Cell Lung Carcinoma 100%
  • Immunotherapy 98%
  • Neoplasms 36%

• OZR4011: OZR Backup mandate: Defining the tumor-cDC cellular interactome to unleash their full potential for cancer immunotherapies

  Laoui, D. & Allonsius, L.

  1/11/22 → 31/10/23

  Project: Fundamental

  • Immunotherapy 100%
  • Neoplasms 61%
  • Dendritic Cells 56%
  • Therapeutics 16%
  • Lung 13%

• IOFACC9B: IOF Accelerator:Integrating a multimodal approach to address current challenges in immunotherapy (INTEGRAL)

  Lahoutte, T., Devoogdt, N., Keyaerts, M., Van Ginderachter, J., Laoui, D., Raes, G., Breckpot, K. & Goyvaerts, C.

  1/10/22 → 31/03/24

  Project: Applied

  • Immunotherapy 100%
  • Molecular Imaging 66%
  • Allergy and Immunology 60%
  • Physiologic Monitoring 60%
  • Drug Development 53%

• ANI297: Tumour-derived dendritic cell vaccination as a novel therapy to prevent metastasis and cancer relapse

  Laoui, D. & Murgaski, A.

  1/01/22 → 31/12/22

  Project: Fundamental

  • Dendritic Cells 100%
  • Neoplasm Metastasis 95%
  • Vaccination 80%
  • Neoplasms 54%
  • Recurrence 51%

• VOPPU95: VOPPU95 - Prijs Kankeronderzoek 2020 - Helena Van Damme

  Van Ginderachter, J., Laoui, D. & Van Damme, H.

  1/01/21 → 30/06/21

  Project: Fundamental

  • Esther 100%
  • Web Sites 76%

• FWOTM1009: Deciphering the dendritic cell compartment in ovarian cancer to assess their potential as tumor vaccines

  Caro, A. A. & Laoui, D.

  1/11/20 → 31/10/24

  Project: Fundamental

  • Ovarian Neoplasms 100%
  • Cancer Vaccines 76%
  • Dendritic Cells 56%

• ANI258: Deciphering the dendritic cell compartment in ovarian cancer to assess their potential as tumor vaccines.

  Laoui, D.

  1/11/20 → 31/10/21

  Project: Fundamental

  • Ovarian Neoplasms 100%
  • Cancer Vaccines 77%
  • Budgets 62%
  • Dendritic Cells 57%

• OZR3751: Bilateral cooperation within the framework of a joint doctoral project: benchfee for joint PhD VUB - KU Leuven, CARO Aarushi Audhut

  Laoui, D.

  8/10/20 → 7/10/24

  Project: Fundamental

• OZR3616: Francqui Collen Start-Up Grant: Damya Laoui 2020 - 2023

  Laoui, D.

  1/09/20 → 31/08/23

  Project: Fundamental

  • Collen 100%
  • Immunotherapy 22%
  • Neoplasms 16%
  • Nobel Prize 12%
  • Tumor Microenvironment 8%

• ANI255: Francqui Collen Start-Up Grant: Damya Laoui 2020 - 2023

  Laoui, D.

  1/09/20 → 31/08/23

  Project: Fundamental

  • Collen 100%
  • Immunotherapy 22%
  • Neoplasms 16%
  • Nobel Prize 12%
  • Tumor Microenvironment 8%

• OZR3588: Financiering FWO hercules: ERA platform: Extended RNA Analysis platform - version 2.0

  Rooman, I., Bouwens, L., Heimberg, H., Neyns, B., Vranken, W., Vanhaecke, T., Massie, A., van Grunsven, L., De Bruyne, E., De Bundel, D., Forsyth, R., Breckpot, K., Van Dooren, S., De Kock, J., Njemini, R. & Laoui, D.

  1/05/20 → 30/04/24

  Project: Fundamental

  • Tissue 100%
  • RNA 85%
  • Gene expression 51%
  • Histology 34%
  • Antibodies 29%

• ANI249: CCR8 blockade for the improvement of immunotherapy in non-small cell lung carcinoma

  Van Ginderachter, J., Devoogdt, N., Laoui, D. & Van Damme, H.

  1/04/20 → 31/03/24

  Project: Fundamental

  • Non-Small Cell Lung Carcinoma 100%
  • Immunotherapy 79%
  • Contracts 65%
  • Neoplasms 18%
  • Tumor Microenvironment 14%

• FWOSB79: A novel cancer therapy that selectively targets tumor-infiltrating regulatory T cells

  Van Ginderachter, J., Laoui, D. & Arnouk, S.

  1/11/19 → 31/10/23

  Project: Fundamental

  • Regulatory T-Lymphocytes 100%
  • Neoplasms 53%
  • Cytotoxic T-Lymphocytes 29%
  • Therapeutics 19%
  • Immunotherapy 16%

• FWOTM956: cDC2s: new players in the tumor microenvironment

  Laoui, D.

  1/10/19 → 30/09/22

  Project: Fundamental

  • Tumor Microenvironment 100%
  • Dendritic Cells 31%
  • Neoplasms 28%
  • Cancer Vaccines 10%
  • Therapeutics 8%

• ANI232: Unraveling the functional B-cell heterogeneity in solid tumors and their impact on cancer immunotherapy

  Laoui, D.

  1/10/19 → 30/09/20

  Project: Fundamental

  • Art 100%
  • Contracts 99%
  • Immunotherapy 75%
  • B-Lymphocytes 66%
  • Neoplasms 27%

• FWOTM969: Unravelling the functional B-cell heterogeneity in solid tumors and their impact on cancer immunotherapy

  Laoui, D. & Bardet, P.

  1/10/19 → 31/10/24

  Project: Fundamental

  • B-Lymphocytes 100%
  • Fees and Charges 96%
  • Immunotherapy 85%
  • Neoplasms 50%
  • B-Lymphocyte Subsets 8%

• FWOSB60: Blockade of the VSIG4 immune checkpoint molecule as novel cancer therapy

  Lebegge, E., Van Ginderachter, J. & Laoui, D.

  1/01/19 → 31/12/22

  Project: Fundamental

  • Fees and Charges 100%
  • Neoplasms 51%
  • Therapeutics 19%
  • Cytotoxic T-Lymphocytes 17%
  • Growth 12%

• FWOKN304: Targeting tumor myeloid cells via combination immunotherapy to enhance the efficacy of therapeutic tumor-derived cDC vaccination strategies

  Laoui, D. & Van Ginderachter, J.

  1/01/18 → 31/12/18

  Project: Fundamental

  • Myeloid Cells 100%
  • Immunotherapy 86%
  • Vaccination 78%
  • neoplasms 74%
  • immunotherapy 54%

• FWOSB45: Tumor-derived dendritic cell vaccination as novel approach for the prevention of cancer relapse

  Van Ginderachter, J., Laoui, D. & Murgaski, A.

  1/01/18 → 31/12/21

  Project: Fundamental

  • Dendritic Cells 100%
  • Neoplasms 63%
  • Vaccination 44%
  • Neoplasm Metastasis 25%
  • Recurrence 24%

• ANI137: Inflammasome activation and IL-B maturation in distinct tumor-associated macrophage and dendritic cell subsets and their impact on tumor characteristics.

  Van Ginderachter, J. & Laoui, D.

  1/11/15 → 28/02/19

  Project: Fundamental

  • Inflammasomes 100%
  • Dendritic Cells 74%
  • Contracts 64%
  • Macrophages 58%
  • Neoplasms 35%